Search research articles
Contact Us
Filters
Showing results (281-290 of 349) with videos related to
Page
of 35
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN
|
July 9, 2015
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy
Donald E Kohan, Hiddo J Lambers Heerspink, Blai Coll, et al.
Diabetes, Obesity & Metabolism
|
February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
Hiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Diabetes, Obesity & Metabolism
|
April 1, 2018
Baseline characteristics and enrichment results from the SONAR trial
Hiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Diabetes Care
|
June 29, 2021
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
Frederik Persson, Peter Rossing, Priya Vart, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
December 2, 2021
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A <i>Post Hoc</i> Analysis of the SONAR Randomized Trial
Simke W Waijer, Ron T Gansevoort, George L Bakris, et al.
American Journal of Nephrology
|
October 18, 2020
Relationship between Serum Uric Acid and Mortality Risk in Hemodialysis Patients: A Multicenter Prospective Cohort Study
Yaya Yang, Xianhui Qin, Yumin Li, et al.
JACC. Heart Failure
|
August 27, 2021
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
John J V McMurray, David C Wheeler, Bergur V Stefánsson, et al.
Journal of the American Society of Nephrology : JASN
|
July 17, 2021
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
Glenn M Chertow, Priya Vart, Niels Jongs, et al.
European Heart Journal
|
April 1, 2021
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
Hiddo J L Heerspink, C David Sjöström, Niels Jongs, et al.
Kidney International Supplements
|
March 10, 2020
Framework for establishing integrated kidney care programs in low- and middle-income countries
Marcello Tonelli, Victoria Nkunu, Cherian Varghese, et al.
Page
of 35
Search research articles
Search
Showing results (281-290 of 349) with videos related to
Sort By:
Page
of 35
Clinical Journal of the American Society of Nephrology : CJASN
|
July 9, 2015
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy
Donald E Kohan, Hiddo J Lambers Heerspink, Blai Coll, et al.
Diabetes, Obesity & Metabolism
|
February 7, 2018
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
Hiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Diabetes, Obesity & Metabolism
|
April 1, 2018
Baseline characteristics and enrichment results from the SONAR trial
Hiddo J L Heerspink, Dennis L Andress, George Bakris, et al.
Diabetes Care
|
June 29, 2021
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
Frederik Persson, Peter Rossing, Priya Vart, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
December 2, 2021
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A <i>Post Hoc</i> Analysis of the SONAR Randomized Trial
Simke W Waijer, Ron T Gansevoort, George L Bakris, et al.
American Journal of Nephrology
|
October 18, 2020
Relationship between Serum Uric Acid and Mortality Risk in Hemodialysis Patients: A Multicenter Prospective Cohort Study
Yaya Yang, Xianhui Qin, Yumin Li, et al.
JACC. Heart Failure
|
August 27, 2021
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
John J V McMurray, David C Wheeler, Bergur V Stefánsson, et al.
Journal of the American Society of Nephrology : JASN
|
July 17, 2021
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
Glenn M Chertow, Priya Vart, Niels Jongs, et al.
European Heart Journal
|
April 1, 2021
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
Hiddo J L Heerspink, C David Sjöström, Niels Jongs, et al.
Kidney International Supplements
|
March 10, 2020
Framework for establishing integrated kidney care programs in low- and middle-income countries
Marcello Tonelli, Victoria Nkunu, Cherian Varghese, et al.
Page
of 35